Volume 3, Issue 4 (November 2024)
Health Science Monitor 2024, 3(4): 292-297 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Samadi Aidenloo N, Motarjemizadeh Q, Hasani Shayan S. Ocular complications in thalassemia major patients treated with deferoxamine: a hospital-based, cross-sectional study. Health Science Monitor 2024; 3 (4) :292-297
URL: http://hsm.umsu.ac.ir/article-1-165-en.html
URL: http://hsm.umsu.ac.ir/article-1-165-en.html
Department of Ophthalmology, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran
Abstract: (597 Views)
Background & Aims: β-thalassemia is a severe hereditary disorder caused by defective globin synthesis. Patients suffering from β-thalassemia major require regular blood transfusion therapy to survive. Sight-threatening ocular abnormalities are quite common among these patients. This study was planned to evaluate the prevalence of ocular complications in multi-transfused patients with β-thalassemia who have been receiving deferoxamine.
Materials & Methods: Thirty thalassemic patients receiving deferoxamine were studied in this cross-sectional descriptive study. All eligible subjects underwent an ophthalmologic examination, including the Humphrey visual field test, measurement of central corneal thickness (CCT), best-corrected visual acuity (BCVA), and central macular thickness (CMT).
Results: Visual field defects were the most prevalent ocular abnormalities, observed in 50% of the studied subjects. Other ocular changes were as follows: bilateral cortical cataract (10%), macular pigmentary stippling (6.7%), punctate cortical opacity (3.3%), nuclear sclerosis cataract (3.3%), and macular pigmentary mottling (3.3%).
Conclusion: The occurrence of ocular problems is common among thalassemic patients which necessitates long-term follow-up and regular ophthalmologic examination for these patients.
Materials & Methods: Thirty thalassemic patients receiving deferoxamine were studied in this cross-sectional descriptive study. All eligible subjects underwent an ophthalmologic examination, including the Humphrey visual field test, measurement of central corneal thickness (CCT), best-corrected visual acuity (BCVA), and central macular thickness (CMT).
Results: Visual field defects were the most prevalent ocular abnormalities, observed in 50% of the studied subjects. Other ocular changes were as follows: bilateral cortical cataract (10%), macular pigmentary stippling (6.7%), punctate cortical opacity (3.3%), nuclear sclerosis cataract (3.3%), and macular pigmentary mottling (3.3%).
Conclusion: The occurrence of ocular problems is common among thalassemic patients which necessitates long-term follow-up and regular ophthalmologic examination for these patients.
Type of Study: Research |
Subject:
Special
Received: 2024/02/24 | Accepted: 2024/07/20 | Published: 2024/11/20
Received: 2024/02/24 | Accepted: 2024/07/20 | Published: 2024/11/20
References
1. Rivella S. Iron metabolism under conditions of ineffective erythropoiesis in beta-thalassemia. Blood. 2019;133:51-58. [DOI] [PMID] [PMCID]
2. Berdoukas V, Coates TD, Cabantchik ZI. Iron and oxidative stress in cardiomyopathy in thalassemia. Free Radical Biology and Medicine. 2015;88:3-9. [DOI] [PMID]
3. Crisponi G, Nurchi VM, Lachowicz JI. Iron Chelation for Iron Overload in Thalassemia. Met Ions in Life Sciences. 2019;19. [DOI]
4. Sridharan K, Sivaramakrishnan G. Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis. Expert Review of Clinical Pharmacology. 2018;641-650. [DOI] [PMID]
5. Neufeld EJ. Update on iron chelators in thalassemia. Hematology Am Soc Hematol Educ Program. 2010;451-455. [DOI] [PMID]
6. Kolnagou A, Kontoghiorghes GJ. Chelation protocols for the elimination and prevention of iron overload in thalassaemia. Frontiers in Bioscience (Landmark Edition). 2018;1082-1098. [DOI] [PMID]
7. Kontoghiorghe CN, Kontoghiorghes GJ. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. Drug Design, Development and Therapy. 2016;10:465-481. [DOI] [PMID] [PMCID]
8. Kontoghiorghes GJ. Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers. Hemoglobin. 2006;30:329-347. [DOI] [PMID]
9. Dewan P, Gomber S, Chawla H, Rohatgi J. Ocular changes in multi-transfused children with β-thalassaemia receiving desferrioxamine: A case-control study. South African Journal of Child Health. 2011;5:11-14. [Google Scholar]
10. Bhoiwala DL, Dunaief JL. Retinal abnormalities in beta-thalassemia major. Survey of Ophthalmology. 2016;61:33-50. [DOI] [PMID] [PMCID]
11. Di Nicola M, Barteselli G, Dell'Arti L, Ratiglia R, Viola F. Functional and Structural Abnormalities in Deferoxamine Retinopathy: A Review of the Literature. Biomed Research International. 2015;2015:249617. [DOI] [PMID] [PMCID]
12. Liaska A, Petrou P, Georgakopoulos CD, Diamanti R, Papaconstantinou D, Kanakis MG, Georgalas I. beta-Thalassemia and ocular implications: a systematic review. BMC Ophthalmology. 2016;16:102. [DOI] [PMID] [PMCID]
13. Jethani J, Marwah K, Patel S, Shah B. Ocular abnormalities in patients with beta thalassemia on transfusion and chelation therapy: our experience. Indian Journal of Ophthalmology. 2010;58:451-452. [DOI] [PMID] [PMCID]
14. Taneja R, Malik P, Sharma M, Agarwal MC. Multiple transfused thalassemia major: ocular manifestations in a hospital-based population. Indian Journal of Ophthalmology. 2010;58:125-130. [DOI] [PMID] [PMCID]
15. Taher A, Bashshur Z, Shamseddeen WA, Abdulnour RE, Aoun E, Koussa S, Baz P. Ocular findings among thalassemia patients. American Journal of Ophthalmology. 2006;142:704-705. [DOI] [PMID]
16. Gartaganis S, Ismiridis K, Papageorgiou O, Beratis NG, Papanastasiou D. Ocular abnormalities in patients with beta thalassemia. American Journal of Ophthalmology. 1989;108:699-703. [DOI] [PMID]
17. Gibson JM, Chaudhuri PR, Rosenthal AR. Angioid streaks in a case of beta thalassaemia major. British Journal of Ophthalmology. 1983;67:29-31. [DOI] [PMID] [PMCID]
18. Barteselli G, Dell'arti L, Finger RP, Charbel Issa P, Marcon A, Vezzola D, et al. The spectrum of ocular alterations in patients with beta-thalassemia syndromes suggests a pathology similar to pseudoxanthoma elasticum. Ophthalmology. 2014;121:709-718. [DOI] [PMID]
19. Gaba A, D'Souza P, Chandra J, Narayan S, Sen S. Ocular changes in β-thalassemia. Annals of Ophthalmology and Glaucoma. 1998;30:357-360. [Google Scholar]
20. Jafari R, Heydarian S, Karami H, Shektaei MM, Dailami KN, Amiri AA, et al. Ocular abnormalities in multi-transfused beta-thalassemia patients. Indian Journal of Ophthalmology. 2015;63:710-715. [DOI] [PMID] [PMCID]
21. Kumble D, Sekhon PK, Devi G. Ocular involvement in beta thalassemia major: a prospective study in an Indian cohort. International Journal of Contemporary Pediatrics. 2017;4:780-782. [DOI]
22. Merchant RH, Punde H, Thacker N, Bhatt D. Ophthalmic Evaluation in Beta-Thalassemia. Indian Journal of Pediatrics. 2017;84:509-514. [DOI] [PMID]
23. Nowroozzadeh MH, Kalantari Z, Namvar K, Meshkibaf MH. Ocular refractive and biometric characteristics in patients with thalassaemia major. Clinical and Experimental Optometry. 2011;94:361-366. [DOI] [PMID]
24. Rahiminejad M, Rahiminejad S, Rahimi M, Baghersalimi A, Inanlou S, Karimi M, et al. Ocular complication and visual evoked potential in β-thalassemia patients on desferal therapy. Research Journal of Biological Sciences. 2009;4:928-932. [Google Scholar]
25. Saif AT, Saif PS, Dabous O. Fundus changes in thalassemia in Egyptian patients. Delta Journal of Ophthalmology. 2017;18:20. [DOI]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
